Answers are grounded in this paper and cite their sources.
Bladder cancer is a heterogeneous malignancy with variable immune infiltration and limited response rates to immune checkpoint blockade. HLA-DQB1, a major histocompatibility complex class II gene involved in antigen presentation, may participate in tumor immune regulation. However, its expression pattern, prognostic relevance, immune microenvironmental associations, and immunotherapy-related significance in bladder cancer remain incompletely characterized. Transcriptomic and clinical data of bladder cancer were obtained from TCGA-BLCA. HLA-DQB1 expression was compared between tumor and normal tissues, and its association with overall survival was evaluated using Kaplan–Meier and Cox regression analyses. Single-sample gene set enrichment analysis was used to estimate immune-cell infiltration. Correlations between HLA-DQB1 and immune checkpoints, antigen-presentation genes, and immune-related modules were assessed using Spearman correlation analysis. Differential expression analysis between HLA-DQB1-high and HLA-DQB1-low tumors was performed using limma, followed by GO and Hallmark GSEA. External validation was conducted using GSE13507. Immunotherapy-related analyses were further performed in the IMvigor210 atezolizumab-treated urothelial carcinoma cohort. Public single-cell visualization was used as exploratory evidence of HLA-DQB1 cellular heterogeneity. In TCGA-BLCA, HLA-DQB1 expression did not differ significantly between tumor and normal tissues and was not significantly associated with overall survival. However, HLA-DQB1 showed strong positive associations with multiple immune-cell infiltration scores, including CD8 T cells, Tfh cells, macrophages, Th1 cells, NK cells, T cells, and Treg cells. HLA-DQB1 was also strongly correlated with antigen-presentation genes and immune-related markers, including HLA-DRA, HLA-DPA1, CD74, CIITA, PDCD1, CTLA4, HAVCR2, CXCL9, and CXCL10. GSEA revealed enrichment of immune activation, antigen presentation, interferon response, and inflammatory pathways in the HLA-DQB1-high group. In GSE13507, although tumor tissues showed lower HLA-DQB1 expression than normal bladder mucosa, the immune associations of HLA-DQB1 were externally reproduced. HLA-DQB1 was significantly correlated with antigen-presentation, myeloid/APC, T-cell-inflamed, and checkpoint-exhaustion module scores in both TCGA-BLCA and GSE13507. In the IMvigor210 cohort, HLA-DQB1 expression tended to be higher in responders, and after adjustment for tumor mutational burden, higher HLA-DQB1 expression was significantly associated with increased odds of response to atezolizumab. HLA-DQB1 expression showed cohort-dependent tumor-versus-normal patterns and was not significantly associated with overall survival in TCGA-BLCA. Across independent transcriptomic cohorts, HLA-DQB1 was consistently associated with MHC-II antigen-presentation-related and immune-inflamed transcriptional programs. Exploratory analysis of an atezolizumab-treated urothelial carcinoma cohort suggested an association with treatment response after adjustment for tumor mutational burden, although this finding requires further validation. Overall, HLA-DQB1 appears to reflect a broader immune-related transcriptional state rather than a validated independent prognostic or immunotherapy response biomarker.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: